Rattigan, K. M. et al. (2023) Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nature Communications, 14, 4634. (doi: 10.1038/s41467-023-40222-z) (PMID:37591854) (PMCID:PMC10435520)

Rattigan, K. M. et al. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, (doi: 10.15252/embr.202256279) (PMID:37489735) (Early Online Publication)

Rattigan, K. M., Zarou, M.-M. and Helgason, G. V. (2023) Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity. Blood, 141(21), pp. 2553-2565. (doi: 10.1182/blood.2022018258) (PMID:36634302)

Ianniciello, A. and Helgason, G. V. (2022) Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia. Autophagy, 18(7), pp. 1734-1736. (doi: 10.1080/15548627.2022.2041152) (PMID:35227175) (PMCID:PMC9298457)

de Beauchamp, L., Himonas, E. and Helgason, G. V. (2022) Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia, 36(1), pp. 1-12. (doi: 10.1038/s41375-021-01416-w) (PMID:34561557) (PMCID:PMC8727299)

Ianniciello, A. et al. (2021) ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 13(613), eabd5016. (doi: 10.1126/scitranslmed.abd5016) (PMID:34586834)